Evidence shows benefit of RSV vaccines as Trump officials push restrictions

Shots to prevent respiratory syncytial virus recommended only for high-risk babies even as experts hail jabs' success

As US officials move to restrict vaccines, including the shots to prevent respiratory syncytial virus (RSV), more evidence is emerging to confirm how dramatically the jabs reduce hospitalizations.

Announced last week as part of new restrictions on one-third of all routine childhood vaccines, RSV shots are now recommended only for high-risk babies, instead of all infants. The Trump administration announcement was led by prominent vaccine critic and health secretary Robert F Kennedy Jr.